Charles J. Fox

Charles J. Fox, MD, serves as a Professor in the Department of Surgery at the University of Maryland School of Medicine, specializing in vascular and trauma surgery with a research focus on hemorrhage control and vascular trauma care. He contributes to the academic community as a reviewer for the Journal of Vascular Surgery and sits on the editorial boards of the Journal of Trauma and Acute Care Surgery and the Journal of Endovascular Trauma Management.

Dr. Fox's educational journey includes a BA from the University of Maryland Baltimore County, an MD from George Washington University, surgical residency at Walter Reed Army Medical Center, and vascular surgery fellowship at the same institution. He maintains board certification through the American Board of Surgery.

His research centers on REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta), vascular trauma management, and resuscitation techniques, informed by his extensive military career as a retired U.S. Army Lieutenant Colonel with deployments to Iraq and Afghanistan. This unique perspective bridges battlefield and civilian trauma care, emphasizing hemorrhage control innovations and critical limb ischemia solutions.

Analysis of his 15 recent publications (2019-2020) reveals a dominant trend in REBOA optimization, trauma registry analytics, and endovascular protocol standardization. His work spans military-civilian translational research, with studies on pelvic hemorrhage control, celiac artery injuries, and dialysis access complications, demonstrating consistent focus on improving trauma outcomes through evidence-based vascular interventions.

Dr. Fox has received notable recognition including:

• Top Doctor in Vascular Surgery by 5280 magazine (2017-2019)
• Bronze Star Medal for combat service in Iraq and Afghanistan

His grant portfolio demonstrates significant leadership in vascular trauma research:

• Active DOD grant (W81XWH2010205, $1M) as CO-PI studying REBOA/TXA effects on dysregulated fibrinolysis in polytrauma (5% effort)
• Multiple completed clinical trials as PI: Critical Limb Ischemia study ($56,773), Humacyte vessel trials for renal disease ($337,370) and trauma ($59,181), and Emergent Truncal Hemorrhage Control study ($334,780)

These projects reflect his commitment to advancing hemorrhage control through rigorous clinical investigation.

Dr. Fox actively collaborates with national trauma registries including the AAST AORTA registry, develops standardized protocols like the Denver Health REBOA protocol, and leads multi-institutional studies that integrate military-civilian expertise to transform vascular trauma care systems.